نتایج جستجو برای: human papillomavirus 18

تعداد نتایج: 1942608  

2014
Fengcai Zhu Juan Li Yuemei Hu Xiang Zhang Xiaoping Yang Hui Zhao Junzhi Wang Jianguo Yang Guodong Xia Qinyong Dai Haiwen Tang Pemmaraju V Suryakiran Sanjoy K Datta Dominique Descamps Dan Bi Frank Struyf

Immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine were evaluated in healthy Chinese females aged 9-45 years in 2 phase IIIB, randomized, controlled trials. Girls aged 9-17 years (ClinicalTrials.gov, NCT00996125) received vaccine (n = 374) or control (n = 376) and women aged 26-45 years (NCT01277042) received vaccine (n = 606) or control (n = 606) at month...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010
Siobhan Sutcliffe Raphael P Viscidi Cathee Till Phyllis J Goodman Ashraful M Hoque Ann W Hsing Ian M Thompson Jonathan M Zenilman Angelo M De Marzo Elizabeth A Platz

Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in rela...

2011
Seung Cheol Kim Yong Sang Song Young-Tae Kim Young Tak Kim Ki-Sung Ryu Bhavyashree Gunapalaiah Dan Bi Hans L Bock Jong-Sup Park

OBJECTIVE The study assessed the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Korean women aged 15-25 years. METHODS Phase IIIB, double-blind, randomised (2:1), multi-centre trial was conducted in Korea from June 2007 to March 2008. The study enrolled 225 women in the HPV (N=149) and placebo (N=76) groups who received three d...

2017
Mariana Goveia Melo RIBEIRO Larissa Doddi MARCOLINO Bruna Ribeiro de Andrade RAMOS Elaine Alves MIRANDA Cleverson Luciano TRENTO Sona JAIN Ricardo Queiroz GURGEL Márcia Guimarães da SILVA Silvio Santana DOLABELLA

Objective The aim of this study was to evaluate the frequency of HPV infection and its genotypes in patients with oral lesions at the Ambulatory of Oral Diagnosis of the Federal University of Sergipe, Brazil. Material and Methods We conducted a molecular study with 21 patients (15 females) aged from two to 83 years with clinically detectable oral lesions. Samples were collected through exfoli...

2004
Al V. Taira Christopher P. Neukermans Gillian D. Sanders

Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We developed disease transmission models that estimated HPV prevalence and infection rates for the population overall, by age group, by level of sexual ...

2009
Raúl Murillo Mónica Molano Gilberto Martínez Juan-Carlos Mejía Oscar Gamboa

Human Papillomavirus (HPV) vaccines have been considered potentially cost-effective for the reduction of cervical cancer burden in developing countries; their effectiveness in a public health setting continues to be researched. We conducted an HPV prevalence survey among Colombian women with invasive cancer. Paraffin-embedded biopsies were obtained from one high-risk and one low-middle-risk reg...

2014
Annika Antonsson Michelle Cornford Susan Perry Marcia Davis Michael P. Dunne David C. Whiteman

The prevalence of human papillomavirus (HPV)-associated head and neck cancers is increasing, but the prevalence of oral HPV infection in the wider community remains unknown. We sought to determine the prevalence of, and identify risk factors for, oral HPV infection in a sample of young, healthy Australians. For this study, we recruited 307 Australian university students (18-35 years). Participa...

2014
Xavier Castellsagué Paulo Naud Song-Nan Chow Cosette M. Wheeler Maria Julieta V. Germar Matti Lehtinen Jorma Paavonen Unnop Jaisamrarn Suzanne M. Garland Jorge Salmerón Dan Apter Henry Kitchener Julio C. Teixeira S. Rachel Skinner Genara Limson Anne Szarewski Barbara Romanowski Fred Y. Aoki Tino F. Schwarz Willy A. J. Poppe F. Xavier Bosch Newton S. de Carvalho Klaus Peters Wiebren A. A. Tjalma Mahboobeh Safaeian Alice Raillard Dominique Descamps Frank Struyf Gary Dubin Dominique Rosillon Laurence Baril

BACKGROUND We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681). METHODS Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegati...

Journal: :Journal of acquired immune deficiency syndromes 2012
Jessica A Kahn Robert D Burk Kathleen E Squires Bill G Kapogiannis Bret Rudy Jiahong Xu René Gonin Nancy Liu Carol Worrell Craig M Wilson

BACKGROUND The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose. METHODS We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV D...

2018

Those rumors are true! In 2006, the Food and Drug Administration [2] (FDA) approved the first vaccine (Gardasil) that protects against certain strains of human papillomavirus (HPV). Over 100 strands of HPV have been identified, and at least 40 strands can affect the genitals. Two strains, HPV-6 and HPV-11, are responsible for approximately 90 percent of genital warts. Two other strains, HPV-16 ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید